Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Pleural Effusion, Malignant 1Lymphoma, Extranodal NK-T-Cell 1

Interventions

pembrolizumab 279Carboplatin 214Cisplatin 145Gemcitabine 144Paclitaxel 142Bevacizumab 115Pemetrexed 112Docetaxel 100Oxaliplatin 78Dexamethasone 77durvalumab 76Fluorouracil 76atezolizumab 75Nivolumab 74Cyclophosphamide 74130-nm albumin-bound paclitaxel 71Fulvestrant 68Cetuximab 63Capecitabine 63Injections 61Leucovorin 60Rituximab 55fludarabine 50Lenalidomide 49venetoclax 43Prednisone 43Irinotecan 42enzalutamide 39Letrozole 39tislelizumab 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × sugemalimab × 90 days × Clear all
NCT05700448 2026-05-27

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

CStone Pharmaceuticals

Phase 3 Not yet recruiting
150 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT06097962 2026-05-20

Safety and Efficacy of NK510 to Treat NSCLC

Base Therapeutics (Shanghai) Co., Ltd.

Phase EARLY_PHASE1 Recruiting
12 enrolled
Thoracic

Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡